Conclusion of non-exclusive rebate agreements pursuant to Section 130a(8) of the German Social Code Book V for the specified active substances, with the possibility of joining under the so-called Open-House procedure.

Summary

The tender concerns the supply of Omalizumab (R03DX05), more precisely a non-exclusive price-reduction agreement with KKH under the Open-House procedure. All suitable pharmaceutical companies may request the participation documents and contract and may join on the same terms. Instead of a bid, the company must submit the participation documents fully completed and signed, and e-invoicing is required.